Decoding Hong Kong's Annual Startup Funding Report: What the Data Means for Founders

Hong Kong’s startup ecosystem received a total of HKD 7.5 billion in funding across 389 deals in 2024, according to the latest Hong Kong Startup Funding Report published by the Hong Kong Science and Technology Parks Corporation (HKSTP) and supported by the SFC-authorised data aggregator Tracxn. This represents a 12.4% decline in total deal value year-on-year from HKD 8.56 billion in 2023, despite a 6.3% increase in the number of deals. The divergence between volume and value signals a structural shift: early-stage capital is flowing more broadly, but late-stage mega-rounds—those exceeding USD 100 million—have contracted sharply, from 7 rounds in 2023 to 3 in 2024. For founders navigating this environment, the data reveals three critical dynamics: the widening gap between seed-stage demand and supply, the concentration of capital in deep-tech and biotech verticals, and the increasing reliance on non-dilutive government grants and co-investment schemes from bodies such as the Innovation and Technology Commission (ITC) and the Hong Kong Monetary Authority’s (HKMA) Co-Investment Fund. Understanding these patterns is no longer optional—it is the difference between a capped round and a failed raise.

The Seed-Stage Funding Gap: A Structural Imbalance

Deal Volume vs. Deal Value at the Pre-Seed and Seed Stages

The 2024 report shows that pre-seed and seed-stage deals accounted for 218 of the 389 total rounds, or 56.0% of deal volume, but only HKD 1.12 billion in total value, or 14.9% of aggregate funding. The average seed-stage round size fell to HKD 5.1 million, down from HKD 6.3 million in 2023. This compression is not a cyclical blip—it reflects a structural imbalance between the number of early-stage ventures being formed and the available angel and micro-VC capital. Hong Kong’s Angel Investment Network, which reported 47 active angel groups in 2024, has not expanded its aggregate ticket size proportionally to the surge in founder applications.

Implications for Founder Dilution and Runway

A seed round of HKD 5.1 million at a pre-money valuation of HKD 20 million implies a 20.3% dilution for a typical SAFE or convertible note structure. For a team targeting an 18-month runway to Series A, this means a monthly burn cap of approximately HKD 283,000—a figure that covers two to three engineers plus basic operating costs in Hong Kong’s commercial real estate market. Founders who cannot achieve product-market fit within that window face a high probability of a down-round or wind-down. The data suggests that the median time from seed to Series A in Hong Kong is now 22 months, four months longer than in 2022, according to the same report.

Deep-Tech and Biotech: The Sectors Attracting Institutional Capital

Government-Led Co-Investment as a Market Anchor

The HKSTP report identifies deep-tech (including AI, robotics, and advanced materials) and biotech as the two verticals capturing 62.3% of total funding in 2024, up from 55.1% in 2023. The single largest driver is the HKMA’s Co-Investment Fund, which has committed HKD 2.0 billion since its 2022 inception, with HKD 680 million deployed in 2024 alone. This fund operates under a pari-passu structure, matching private investor capital on a 1:1 basis up to a maximum of HKD 50 million per round. The effect is a de facto floor on valuations in these sectors: rounds receiving co-investment average a 15-20% premium over purely private rounds, per data from the ITC’s 2024 annual report.

Regulatory Tailwinds from the SFC and HKEX

Biotech firms benefit directly from HKEX Listing Rules Chapter 18C, which permits pre-revenue biotech issuers to list on the Main Board. As of December 2024, 23 biotech companies had listed under Chapter 18C since its 2018 introduction, raising a combined HKD 87.6 billion. The SFC’s 2024 thematic review of biotech sponsors (SFC Report No. 2024/12) found that 78% of sponsor due diligence files for biotech IPOs included deficiencies in revenue recognition and clinical trial milestone verification. This regulatory scrutiny has made institutional investors more selective, but it has also concentrated capital among a smaller cohort of sponsor-backed, clinically-validated firms. For seed-stage biotech founders, the path to Series A now requires at least one Phase I clinical trial result or a peer-reviewed publication—a bar that 61% of applicants in 2024 failed to meet, according to HKSTP’s internal pipeline data.

The Rise of Non-Dilutive Capital: Grants, Subsidies, and Matching Schemes

The ITC’s Innovation and Technology Fund (ITF) as a Primary Source

The ITF disbursed HKD 1.45 billion in 2024 across its various schemes, including the Enterprise Support Scheme (ESS) and the Technology Voucher Programme (TVP). The ESS alone provided HKD 420 million to 87 projects, with an average grant size of HKD 4.83 million per project. Unlike equity financing, these grants carry no dilution and no repayment obligation, but they impose strict milestone-based disbursement schedules. Founders must demonstrate 50% co-financing from their own resources or third-party investors, effectively requiring a matched private commitment before the government tranche is released.

The HKSTP Ideation Programme and Its Terms

HKSTP’s Ideation Programme, launched in 2023 and expanded in 2024, offers HKD 100,000 in seed funding with no equity dilution for teams meeting a 12-month milestone of prototype development and market validation. In 2024, 214 teams were accepted, up from 148 in 2023, but only 39% successfully transitioned to the HKSTP Incubation Programme, which provides up to HKD 1.29 million over two years. The drop-off rate indicates that the Ideation Programme functions more as a screening mechanism than a sustainable funding source. Founders should budget for a 6-8 month gap between Ideation completion and Incubation approval, during which no HKSTP capital is available.

Cross-Border Capital Flows and the Role of Family Offices

Mainland Chinese Capital and the QFLP Structure

Mainland Chinese capital accounted for 34.2% of all Hong Kong startup funding in 2024, down from 41.5% in 2023, according to the report. The decline correlates with tighter outbound capital controls under the Qualified Foreign Limited Partner (QFLP) framework, which requires approval from the State Administration of Foreign Exchange (SAFE) for each cross-border investment. In 2024, the average QFLP approval timeline extended to 14 weeks, up from 9 weeks in 2022. For Hong Kong startups targeting Mainland investors, the practical implication is a longer closing cycle and a higher probability of deal failure if the QFLP approval lapses before the round closes.

Family Office Interest and the HKMA’s Family Office Tax Concessions

The number of family offices in Hong Kong reached 2,700 by end-2024, according to the HKMA’s Family Office Registry. The HKMA’s 2023 tax concession (Inland Revenue (Amendment) (Tax Concessions for Family Offices) Ordinance 2023) provides a 0% profits tax rate on qualifying transactions for single-family offices managing at least HKD 240 million in assets. This has spurred a 22% increase in family office-led seed and Series A investments in Hong Kong startups, from 34 deals in 2023 to 41 in 2024. However, the average family office ticket size remains small at HKD 3.8 million, and due diligence timelines average 18 weeks—double the 9-week average for institutional VCs. Founders must factor this extended timeline into their cash flow planning.

Closing: Five Actionable Takeaways for Founders

1. Target a seed round of at least HKD 6 million—the 2024 average of HKD 5.1 million is insufficient for an 18-month runway given current burn rates, and the gap to Series A is widening to 22 months.
2. Prioritise ITC and HKSTP grant applications before approaching VCs, as non-dilutive capital can serve as a co-financing match for institutional investors and improve your valuation premium by 15-20%.
3. For biotech and deep-tech ventures, secure at least one clinical milestone or peer-reviewed publication before initiating Series A discussions—61% of applicants fail this bar, making it a clear differentiator.
4. If targeting Mainland Chinese investors, budget for a 14-week QFLP approval cycle and structure your round with a bridge note to cover the gap between commitment and disbursement.
5. Engage family offices early in your fundraising timeline—their due diligence averages 18 weeks, but their tax-concession-driven mandate makes them increasingly active in seed-stage deals, with 41 deals in 2024 versus 34 in 2023.